PL2753617T3 - Podstawione piperazyną pochodne benzotiofenu jako środki przeciwpsychotyczne - Google Patents

Podstawione piperazyną pochodne benzotiofenu jako środki przeciwpsychotyczne

Info

Publication number
PL2753617T3
PL2753617T3 PL12766485.2T PL12766485T PL2753617T3 PL 2753617 T3 PL2753617 T3 PL 2753617T3 PL 12766485 T PL12766485 T PL 12766485T PL 2753617 T3 PL2753617 T3 PL 2753617T3
Authority
PL
Poland
Prior art keywords
piperazine
antipsychotic agents
benzothiophene derivatives
substituted benzothiophene
substituted
Prior art date
Application number
PL12766485.2T
Other languages
English (en)
Inventor
Hiroshi Yamashita
Yohji Sakurai
Motoyuki Miyamoto
Yuichi Nakamura
Hideaki Kuroda
Takuya Minowa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2753617T3 publication Critical patent/PL2753617T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/695Silicon compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
PL12766485.2T 2011-09-08 2012-09-07 Podstawione piperazyną pochodne benzotiofenu jako środki przeciwpsychotyczne PL2753617T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161532393P 2011-09-08 2011-09-08

Publications (1)

Publication Number Publication Date
PL2753617T3 true PL2753617T3 (pl) 2016-10-31

Family

ID=46940565

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12766485.2T PL2753617T3 (pl) 2011-09-08 2012-09-07 Podstawione piperazyną pochodne benzotiofenu jako środki przeciwpsychotyczne

Country Status (31)

Country Link
US (9) US9260420B2 (pl)
EP (1) EP2753617B9 (pl)
JP (1) JP6193848B2 (pl)
KR (1) KR101998441B1 (pl)
CN (1) CN103781783B (pl)
AR (1) AR087809A1 (pl)
AU (1) AU2012305212B2 (pl)
BR (1) BR112014005235B1 (pl)
CA (1) CA2847339C (pl)
CO (1) CO6930362A2 (pl)
CY (1) CY1118753T1 (pl)
DK (1) DK2753617T3 (pl)
EA (1) EA028160B1 (pl)
ES (1) ES2572934T3 (pl)
HK (1) HK1195550A1 (pl)
HR (1) HRP20160824T2 (pl)
HU (1) HUE027746T2 (pl)
IL (1) IL231116B (pl)
JO (1) JO3227B1 (pl)
MX (1) MX359515B (pl)
MY (1) MY196864A (pl)
PL (1) PL2753617T3 (pl)
PT (1) PT2753617T (pl)
RS (1) RS54894B9 (pl)
SG (2) SG11201400148QA (pl)
SI (1) SI2753617T1 (pl)
SM (1) SMT201600205B (pl)
TW (1) TWI568728B (pl)
UA (1) UA112993C2 (pl)
WO (1) WO2013035892A1 (pl)
ZA (1) ZA201401433B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JO3227B1 (ar) * 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
TW201332572A (zh) * 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β-環糊精之藥物製劑
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JP2014196292A (ja) * 2013-03-07 2014-10-16 大塚製薬株式会社 医薬
CN104447723A (zh) * 2014-11-28 2015-03-25 瑞阳制药有限公司 7-(4-(4-(苯并[b]噻吩基)-1-哌嗪基)丁氧基)-2(1H)-喹啉酮的制备方法
CN104829603A (zh) * 2015-05-19 2015-08-12 杭州新博思生物医药有限公司 A晶型依匹唑派盐酸盐及其制备方法
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
PL233778B1 (pl) 2016-07-19 2019-11-29 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Sposob wytwarzania brekspiprazolu oraz zastosowanie zwiazkow posrednich w sposobie wytwarzania brekspiprazolu
CN109716411B (zh) * 2016-09-08 2021-06-25 福特汽车公司 用以监测驾驶员的活动水平的方法和设备
CN106699745A (zh) * 2016-12-14 2017-05-24 上海博志研新药物技术有限公司 一种依匹哌唑甲醇合物、晶型a、及其制备方法和应用
US20180265472A1 (en) * 2017-03-17 2018-09-20 Scinopharm Taiwan, Ltd. Process for preparing aripiprazole lauroxil and intermediates thereof
CN107628999B (zh) * 2017-10-25 2019-07-02 苏州华健瑞达医药技术有限公司 阿立哌唑十二烷酸酯的制备方法
CN109988162A (zh) * 2017-12-29 2019-07-09 武汉兴华智慧医药科技有限公司 一种依匹哌唑衍生物及其制备方法
CN110218209B (zh) * 2018-03-02 2022-09-30 上海现代药物制剂工程研究中心有限公司 一种依匹哌唑月桂酸酯的晶型a、其制备方法及应用
CN108947990A (zh) * 2018-07-20 2018-12-07 成都苑东生物制药股份有限公司 一种苯并噻吩类化合物的制备方法
TWI827783B (zh) * 2019-01-11 2024-01-01 昱展新藥生技股份有限公司 K他命雙羥萘酸鹽及其用途
EP4175638A1 (en) * 2020-07-06 2023-05-10 Tactogen Inc. Advantageous benzothiophene compositions for mental disorders or enhancement
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
CN114044772A (zh) * 2021-11-29 2022-02-15 浙江国邦药业有限公司 一种依匹哌唑合成方法及其中间体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200500342A1 (ru) * 2002-09-17 2005-08-25 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си Гетероциклические замещённые пиперазины для лечения шизофрении
MXPA05006857A (es) 2002-12-27 2005-08-18 Otsuka Pharma Co Ltd Derivados de carbostirilo e inhibidores de la recaptacion de serotonina para el tratamiento de desordenes en el humor.
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US20050254575A1 (en) 2004-05-12 2005-11-17 Nokia Corporation Multiple interoperability points for scalable media coding and transmission
DE102004031052A1 (de) 2004-06-25 2006-01-12 Bühler AG System und Verfahren zur Mahlgut-Charakterisierung in einem Walzenstuhl
WO2006011246A1 (ja) 2004-07-29 2006-02-02 Magie Pression Co., Ltd. ポリ乳酸糸で構成された布帛のプリーツ形成法およびプリーツ布帛
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
WO2006111246A1 (de) 2005-04-18 2006-10-26 Loi Thermprocess Gmbh Industrieofen
JP4540700B2 (ja) 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
JP2011136906A (ja) * 2008-04-18 2011-07-14 Otsuka Pharmaceut Co Ltd 複素環化合物
FI2445502T4 (fi) 2009-06-25 2023-01-13 Heterosyklisiä yhdisteitä neurologisten ja psykologisten häiriöiden hoitamiseksi
JP5732453B2 (ja) 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド Nh酸性化合物のプロドラッグ
AU2010339689B2 (en) 2010-01-07 2015-02-19 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
AU2011270701B2 (en) 2010-06-24 2015-05-14 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
WO2012088441A1 (en) 2010-12-23 2012-06-28 Alkermes, Inc. Multi- api loading prodrugs
PL3156056T3 (pl) 2011-03-18 2024-04-29 Alkermes Pharma Ireland Limited Kompozycje farmaceutyczne zawierające estry sorbitanu
JO3227B1 (ar) * 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان

Also Published As

Publication number Publication date
DK2753617T3 (en) 2016-07-25
US20200061056A1 (en) 2020-02-27
AU2012305212A1 (en) 2014-04-24
TWI568728B (zh) 2017-02-01
PT2753617T (pt) 2016-07-13
US9260420B2 (en) 2016-02-16
EP2753617B9 (en) 2017-01-25
UA112993C2 (uk) 2016-11-25
US20180092907A1 (en) 2018-04-05
JP6193848B2 (ja) 2017-09-06
BR112014005235A2 (pt) 2017-04-11
EA201490585A1 (ru) 2014-08-29
SG11201400148QA (en) 2014-03-28
HRP20160824T2 (hr) 2017-05-19
US20150045356A1 (en) 2015-02-12
EP2753617A1 (en) 2014-07-16
MX2014002254A (es) 2014-04-30
IL231116A0 (en) 2014-04-30
ES2572934T9 (es) 2017-05-08
MX359515B (es) 2018-10-01
US20160143905A1 (en) 2016-05-26
KR20140069109A (ko) 2014-06-09
US9539252B2 (en) 2017-01-10
CA2847339C (en) 2020-03-10
ZA201401433B (en) 2015-05-27
TW201326160A (zh) 2013-07-01
EP2753617B1 (en) 2016-04-13
US20190167672A1 (en) 2019-06-06
AU2012305212B2 (en) 2016-12-08
CY1118753T1 (el) 2017-07-12
WO2013035892A1 (en) 2013-03-14
US20170071933A1 (en) 2017-03-16
HRP20160824T1 (hr) 2016-08-26
SMT201600205B (it) 2016-08-31
CA2847339A1 (en) 2013-03-14
CN103781783B (zh) 2016-12-07
NZ621837A (en) 2015-06-26
US20210052575A1 (en) 2021-02-25
RS54894B1 (sr) 2016-10-31
JP2014526435A (ja) 2014-10-06
JO3227B1 (ar) 2018-03-08
SG10201601731RA (en) 2016-04-28
CO6930362A2 (es) 2014-04-28
CN103781783A (zh) 2014-05-07
HK1195550A1 (zh) 2014-11-14
IL231116B (en) 2019-09-26
KR101998441B1 (ko) 2019-07-09
MY196864A (en) 2023-05-05
HUE027746T2 (en) 2016-10-28
RS54894B9 (sr) 2019-12-31
EA028160B1 (ru) 2017-10-31
US20180318294A1 (en) 2018-11-08
AR087809A1 (es) 2014-04-16
ES2572934T3 (es) 2016-06-03
US20230099694A1 (en) 2023-03-30
BR112014005235B1 (pt) 2022-03-29
SI2753617T1 (sl) 2016-08-31

Similar Documents

Publication Publication Date Title
HRP20160824T1 (hr) Derivati benzotiofena supstituirani piperazinom kao antipsihotički agensi
AP3336A (en) Fluoro-pyridinone derivatives useful as antibacterial agents
IL227664A0 (en) New heterocyclic histories
SG10201601802YA (en) Dispiropyrrolidine derivatives
IL231229A0 (en) New history of dihydroquinoline-2-one
IL247638B (en) History of heteroaryl piperidine
EP2709609A4 (en) HETEROCYCLIC COMPOUNDS
ZA201307428B (en) Thiazole derivatives
HK1191653A1 (zh) -糖苷衍生物
IL231950B (en) Aryl-quinoline derivatives
EP2721029A4 (en) IMIDAZOPYRIDIN-2-ONE DERIVATIVES
IL233001A0 (en) New iso-ergoline histories
SI2766342T1 (sl) Derivati fenil-gvanidina
ZA201308049B (en) 3-ureidoisoquinolin-8-yl derivatives
ZA201209319B (en) Cyclopropyl-indole derivatives
GB201100830D0 (en) Printing composition